Hello, I am Meriem Bouslouk-Marx
the Founder of MBM Future Health
I advise global companies on evidence-based decision making as basis for reimbursement of their medicines in Germany. The benefit assessment of new medicinal products has been the centre of my work for 15 years – 10 years at Germany’s top health policy body, the G-BA.
MORE ABOUT ME:
G-BA and AMNOG
When Germany introduced AMNOG – the legislation on the benefit assessment of medicinal products – in 2011, I joined the initial small team at the Federal Joint Committee G‑BA in charge of implementing the procedure. In this position, I prepared binding national decisions published in the Federal Gazette. My main responsibilities included conducting Scientific Consultations with pharmaceutical companies and involved Regulatory Authorities on clinical trial design. In addition, I assessed dossiers to prepare G‑BA Resolutions.
Orphan Drugs
My particular focus from the outset was on the benefit assessment of new orphan drugs. At the G-BA, I co-ordinated the specific health policy procedure for their assessment in Germany.
International
From the start in 2011, I was entrusted to promote the G-BA’s work outside Germany: In lectures and speeches – within and outside the G‑BA – I fostered partnerships with European and international organisations. Until today, national and international relationships are an asset. Besides German, I speak French, Arabic and English as well as basic Spanish.
Education and Early Career
After my French Baccalauréat at Lycée Descartes in Rabat, Morocco, I graduated with a PhD in Dental Medicine from the Friedrich Schiller University in Jena, Germany and hold a postgraduate Master of Science in International Health from the Charité – Universitätsmedizin Berlin. At the beginning of my career, I worked with Public Health projects in Africa, also in dental offices in Berlin.
‘Combining integrity and enthusiasm induces the best value.’
Equipped with my experience, I have been supporting my clients worldwide for several years with my company MBM Future Health.
Relevant publications
Expert Opinion
G-BA benefit assessment of new orphan drugs in Germany
My experience at the Federal Joint Committee G-BA with the benefit assessment of orphan drugs in Germany under AMNOG. Facts on policy and scientific procedure.
Pharmaceutical Executive
Efficacy Controversy Hits European COVID-19 Vaccine Rollout
Donald Macarthur and I discuss post-approval findings of national committees in Europe for the use of a new COVID-19 vaccine in their populations.
Tagesspiegel Background
Mit der EMA auf der Überholspur/With EMA on the fast track
I take a stance on the political decisions and procedures for approval and distribution of vaccines in Germany and in the EU, also in the light of public criticism.
In action
Lecturer and Speaker at the Market Access Society (MAS). MORE INFORMATION
Adviser at Project HERCULES, a Duchenne UK Global Collaboration. MORE INFORMATION
Speaker at the Brazilian Health Regulatory Agency Anvisa. GENE AND ADVANCED THERAPIES: Creating Value in the Patient Journey and the Health System. MORE INFORMATION
Adviser with the Alliance for Regenerative Medicine (ARM). Getting Ready: Recommendations for Timely Access to Advanced Therapy Medicinal Products (ATMPs) in Europe. MORE INFORMATION
In references
AMED, Japan Agency for Medical Research and Development (2020) Development Trend Survey of Ultra Orphan Drugs. MORE INFORMATION
Schoonveld, E. (2020). The Price of Global Health: Drug Pricing Strategies to Balance Patient Access and the Funding of Innovation (3rd ed.). Routledge. MORE INFORMATION
European Commission (2019) Study to Support the Evaluation of the EU Orphan Regulation. MORE INFORMATION
OECD, Organisation for Economic Co-operation and Development (2018) Pharmaceutical Reimbursement and Pricing in Germany. MORE INFORMATION
Recent News
G-BA resolutions on afamelanotide for the rare disease erythropoietic protoporphyria RAPS EURO Convergence Europe in Berlin on 7 May 2024
Obstacles for patient access to medicines can happen at different stages of a medicine's life cycle. Therefore, marketing authorisation should not...
Benefit assessment in Germany – G-BA resolutions on Zolgensma Market Access Day in Paris on 2 October 2023
The global community of market access professionals met in France on 2 October 2023 at the Market Access Day – the first post-pandemic event of the...
Spesolimab: Does the benefit assessment of medicines for rare diseases need more flexibility? The case of spesolimab (Spevigo®)
After Boehringer Ingelheim’s announcement to withdraw a medicine for the treatment of a rare skin disease from the German market on 29 August 2023,...